Perturbations of the ETA-ETB axis have been implicated in atherosclerosis and pulmonary artery hypertension, and ET receptor antagonists have been used successfully to treat both essential and pulmonary hypertension [18]. Here, EDNRA is linked to pulmonary hypertension.